An association of soluble CD40 ligand (CD154) with adverse reactions to platelet transfusions

Transfusion

Volumn 46, Issue 10, 2006, Pages 1813-1821

  Blumberg, Neil ^a   Gettings, Kelly F ^b   Turner, Chantal ^b   Heal, Joanna M ^b   Phipps, Richard P ^b  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CD40 LIGAND; INTERLEUKIN 6; INTERLEUKIN 8; MONOCYTE CHEMOTACTIC PROTEIN 1; RANTES; THROMBOCYTE CONCENTRATE;

ALLERGY; ARTICLE; BLOOD TRANSFUSION REACTION; COHORT ANALYSIS; FEVER; HEMATOLOGIC MALIGNANCY; HUMAN; INFLAMMATION; LEUKAPHERESIS; LEUKOPENIA; PROSPECTIVE STUDY; THROMBOCYTE TRANSFUSION;

ADULT; AGED; BLOOD PLATELETS; BLOOD PRESERVATION; CD40 LIGAND; CYTOKINES; FEMALE; HEMATOLOGIC NEOPLASMS; HUMANS; INFLAMMATION; LEUKOPENIA; MALE; MIDDLE AGED; PLATELET TRANSFUSION; PROSPECTIVE STUDIES;

EID: 33748932562     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/j.1537-2995.2006.00979.x     Document Type: Article

References (26)

1. Muylle L, Wouters E, DeBock R, Peetermans ME. Reactions to platelet transfusion: the effect of the storage time of the concentrate. Transfus Med 1992;2:289-93.
2. Heddle NM, Klama L, Singer J, et al. The role of the plasma from platelet concentrates in transfusion reactions. N Engl J Med 1994;331:625-8.
3. Snyder EL. Transfusion reactions: state-of-the-art 1994. Vox Sang 1994;67(Suppl 3):143-6.
4. Muylle L, Joos M, Wouters E, De Bock R, Peetermans ME. Increased tumor necrosis factor α (TNFα), interleukin 1, and interleukin 6 (IL-6) levels in the plasma of stored platelet concentrates: Relationship between TNFα and IL-6 levels and febrile transfusion reactions. Transfusion 1993;33:195-9.
5. Stack G, Snyder EL. Cytokine generation in stored platelet concentrates. Transfusion 1994;34:20-5.
6. Heddle NM, Blajchman MA, Meyer RM, et al. A randomized controlled trial comparing the frequency of acute reactions to plasma-removed platelets and prestorage WBC-reduced platelets. Transfusion 2002;42:556-66.
7. Novotny VM, Van Doorn R, Witvliet MD, Claas FH, Brand A. Occurrence of allogeneic HLA and non-HLA antibodies after transfusion of prestorage filtered platelets and red blood cells: a prospective study. Blood 1995;85:1736-41.
8. Vo TD, Cowles J, Heal JM, Blumberg N. Platelet washing to prevent recurrent febrile reactions to leucocyte-reduced transfusions. Transfus Med 2001;11:45-7.
9. Blumberg N, Heal JM, Rowe JM. A randomized trial of washed red blood cell and platelet transfusions in adult acute leukemia [ISRCTN76536440]. BMC Blood Disord 2004;4:6.
10. Wang SE, Lara PN Jr, Lee-Ow A, et al. Acetaminophen and diphenhydramine as premedication for platelet transfusions: a prospective randomized double-blind placebo-controlled trial. Am J Hematol 2002;70:191-4.
11. Patterson BJ, Freedman J, Blanchette V, et al. Effect of premedication guidelines and leukoreduction on the rate of febrile nonhaemolytic platelet transfusion reactions. Transfus Med 2000;10:199-206.
12. Klinger MHF, Kluter H. Blood platelets are circulating stores for adhesive proteins, inflammatory mediators, and immunoglobulins - role in nonhemolytic transfusion reactions [review]. Infusionsther Transfusionsmed 1999;26:20-5.
13. Heddle NM. Pathophysiology of febrile nonhemolytic transfusion reactions. Curr Opin Hematol 1999;6:420-6.
14. Henn V, Slupsky JR, Grafe M, et al. CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature 1998;391:591-4.
15. Danese S, Fiocchi C. Platelet activation and the CD40/CD40 ligand pathway: mechanisms and implications for human disease. Crit Rev Immunol 2005;25:103-21.
16. Danese S, Fiocchi C. Atherosclerosis and inflammatory bowel disease: sharing a common pathogenic pathway? Circulation 2003;107:e52.
17. Fan Y, Ge Y, Zhu H, et al. Characterization and application of two novel monoclonal antibodies against CD40L: epitope and functional studies on cell membrane CD40L and studies on the origin of soluble serum CD40L. Tissue Antigens 2004;64:257-63.
18. Zhang Y, Cao HJ, Graf B, et al. CD40 engagement upregulates cyclooxygenase-2 expression and protaglandin E2 production in human lung fibroblasts. J Immunol 1998;160:1053-7.
19. Blumberg N, Phipps RP, Kaufman J, Heal JM. The causes and treatment of reactions to platelet transfusions. Transfusion 2003;43:291-2;author reply 292.
20. Phipps RP, Kaufman J, Blumberg N. Platelet derived CD154 (CD40 ligand) and febrile responses to transfusion. Lancet 2001;357:2023-4.
21. Ivanov AI, Romanovsky AA. Prostaglandin E2 as a mediator of fever: synthesis and catabolism. Front Biosci 2004;9:1977-93.
22. Akbiyik F, Ray DM, Gettings KF, et al. Human bone marrow megakaryocytes and platelets express PPARgamma, and PPARgamma agonists blunt platelet release of CD40 ligand and thromboxanes. Blood 2004;104:1361-8.
23. Phipps RP, Stein SH, Roper RL. A new view of prostaglandin E regulation of the immune response. Immunol Today 1991;12:349-52.
24. Phipps R, Stein S, Roper R. A new view of PGE2 regulation of the immune response. Immunol Today 1991;12:349-52.
25. Silliman CC, Ambruso DR, Boshkov LK. Transfusion-related acute lung injury. Blood 2005;105:2266-73.
26. Blumberg N, Boshkov LK, Silliman CC, et al. CD40 ligand (CD154) as a cofactor in the development of transfusion related acute lung injury [abstract]. Blood 2004;104:237a-8a.